Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco‐epidemiological approach

To estimate inflammatory bowel disease (IBD) prevalence in Portugal from 2003 to 2007, and to obtain disease, sex and age specific estimates.

[1]  A. Costa-Pereira,et al.  Ulcerative colitis in a Southern European country: A national perspective , 2010, Inflammatory bowel diseases.

[2]  M. Cravo,et al.  Crohn's disease in a southern European country: Montreal classification and clinical activity , 2009, Inflammatory bowel diseases.

[3]  M. Cravo,et al.  Inflammatory Bowel Disease: A Patient’s and Caregiver’s Perspective , 2009, Digestive Diseases and Sciences.

[4]  A E Ades,et al.  Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. , 2008, Biostatistics.

[5]  Catherine H Mercer,et al.  Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data , 2008 .

[6]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[7]  S. Hanauer,et al.  Treatment of inflammatory bowel disease: a review of medical therapy. , 2008, World journal of gastroenterology.

[8]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[9]  P. Lakatos.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.

[10]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[11]  P. Lakatos,et al.  Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? , 2006, Postgraduate Medical Journal.

[12]  R. Bergman,et al.  Systematic review: the use of mesalazine in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[13]  J. Cabrita,et al.  Using a pharmacoepidemiological approach to estimate diabetes type 2 prevalence in Portugal , 2006, Pharmacoepidemiology and drug safety.

[14]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[15]  Alex J. Sutton,et al.  Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .

[16]  M. Keisu,et al.  Sulfasalazine associated agranulocytosis in Sweden 1972–1989 , 1992, European Journal of Clinical Pharmacology.

[17]  Nicky J Welton,et al.  A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence , 2005 .

[18]  V. Binder.  Epidemiology of IBD during the twentieth century: an integrated view. , 2004, Best practice & research. Clinical gastroenterology.

[19]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[20]  D. Purdie.  Statistical Methods in Medical Research, 4th edn , 2003 .

[21]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[22]  W. Sandborn,et al.  Epidemiology of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[23]  P. J. Kelly,et al.  Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.

[24]  R. Pounder,et al.  Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort , 1998, BMJ.

[25]  P. Munkholm.  Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. , 1997, Danish medical bulletin.

[26]  J. Lennard-jones,et al.  Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). , 1996, Gut.

[27]  D. Palli,et al.  A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). , 1996, Scandinavian journal of gastroenterology.

[28]  R. Da Cas,et al.  Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome , 1996, Alimentary pharmacology & therapeutics.

[29]  F. Sartor,et al.  Results of an epidemiological study on drug-treated intraocular hypertension in Belgium. , 1996, Journal of clinical epidemiology.

[30]  F. Sartor,et al.  Estimate of disease prevalence using drug consumption data. , 1995, American journal of epidemiology.

[31]  H. Jick,et al.  The Risk of Sulfasalazine‐ and Mesalazine‐Associated Blood Disorders , 1995, Pharmacotherapy.

[32]  G. Corrao,et al.  Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease , 1994, Alimentary pharmacology & therapeutics.

[33]  D. Vicent,et al.  Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. , 1994, Journal of clinical gastroenterology.

[34]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[35]  C. Prantera,et al.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease , 1992 .

[36]  V. Jureša,et al.  Ulcerative colitis in Zagreb, Yugoslavia: incidence and prevalence 1980-1989. , 1991, International journal of epidemiology.

[37]  S. Kreiner,et al.  Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. , 1991, Scandinavian journal of gastroenterology.

[38]  V. Jureša,et al.  Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. , 1991, International journal of epidemiology.

[39]  A. Sonnenberg,et al.  Geographic variation of inflammatory bowel disease within the United States. , 1991, Gastroenterology.

[40]  M. Scheurlen,et al.  Epidemiology of inflammatory bowel disease in the county of Tübingen (West Germany). , 1989, Scandinavian journal of gastroenterology. Supplement.

[41]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[42]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .